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TGF-b blockade significantly slows tumor growth through many mechanisms, including activation of CD8+
T cells and macrophages. Here, we show that TGF-b blockade also increases neutrophil-attracting chemo-
kines, resulting in an influx of CD11b+/Ly6G+ tumor-associated neutrophils (TANs) that are hypersegmented,
more cytotoxic to tumor cells, and express higher levels of proinflammatory cytokines. Accordingly, following
TGF-b blockade, depletion of these neutrophils significantly blunts antitumor effects of treatment and
reduces CD8+ T cell activation. In contrast, in control tumors, neutrophil depletion decreases tumor growth
and results in more activated CD8+ T cells intratumorally. Together, these data suggest that TGF-bwithin the
tumor microenvironment induces a population of TANwith a protumor phenotype. TGF-b blockade results in
the recruitment and activation of TANs with an antitumor phenotype.INTRODUCTION
Mounting evidence suggests that the immunosuppressive cyto-
kine TGF-b is overexpressed by tumors and plays a significant
role in blocking immune responses and affecting tumor progres-
sion. The pivotal role of TGF-b in suppressing antitumor immune
responses has made it a logical target for the development of
antagonists (Bierie and Moses, 2006). TGFb blockers (soluble
receptors/antibodies) and TGFb receptor inhibitors have anti-
tumor effects that, in several models, are due primarily to CD8+
T cell-dependent immunologic mechanisms (Ge et al., 2006;
Nam et al., 2008; Suzuki et al., 2007).
In addition to suppressing T cell functions, it has been shown
that TGF-b also has an impact on myeloid cell functions. The
tumor microenvironment polarizes TAMs toward a protumor
(M2) versus an antitumor (M1) phenotype (Allavena et al., 2008).
Since TGF-b can alter macrophage cell function and phenotype
in vitro (Lee et al., 2007; Tsunawaki et al., 1988), it may play anCimportant role in regulating macrophage phenotype in vivo as
well. Although it is less well studied, TGF-b has also been noted
to inhibit neutrophil activity (i.e., degranulation) (Shen et al.,
2007). Early studies suggested that TGF-b had chemoattractant
activity for neutrophils at very low concentrations (Reibman
et al., 1991), and more recent studies have suggested that block-
ing the TGF-bpathway increases the recruitment of neutrophils in
some types of chronic disease states (Allen et al., 2008).
In recently published studies, we used a small, orally available
type I TGFb receptor (Alk-5/Alk-4) kinase inhibitor (SM16) and
showed that TGF-b receptor blockade increased the percentage
and activation of intratumoral CD8+ T cells and was able to
augment immunotherapy (Kim et al., 2008; Suzuki et al., 2007).
In addition, blockade of TGF-b function led to an influx of myeloid
cells (marked by CD11b positivity on FACS) into tumors. The
goals of this study were to evaluate the effect of SM16 on the
myeloid cell phenotype of tumors and to explore how these
changes might affect CD8+ T cell function.SIGNIFICANCE
The role of tumor-associated neutrophils (TANs) in tumor biology is unclear. It is well established that the tumor microen-
vironment polarizes tumor-associated macrophages (TAMs) toward a protumor (M2) versus an antitumor (M1) phenotype.
Our data support a paradigm in which resident TANs acquire a protumor phenotype (similar to M2), largely driven by TGF-b
to become ‘‘N2’’ neutrophils. After TGF-b blockade, neutrophils acquire an antitumor phenotype to become ‘‘N1’’ TANs
(similar to M1). This paradigm suggests that TANs are a double-edged sword, capable of being pro- or antitumorigenic,
depending on the tumor microenvironment. Our study also shows another mechanism by which TGF-b can enhance tumor
growth and supports the potential utility of TGF-b blockade to inhibit tumor growth.ancer Cell 16, 183–194, September 8, 2009 ª2009 Elsevier Inc. 183
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Polarization of TAN by TGF-bFigure 1. SM16 Causes an Influx of CD11b+
Ly6G+ Granulocytic Cells into Tumors
(A and B) Flow cytometry was performed on digested
tumors from animals treated for 1 week with control
chow (left columns) or SM16 chow (right columns) in
each of the three flank tumors: AB12 (n = 26), LKR
(n = 5) and TC-1 (n = 9–10). (A) summarizes the
percentage of CD11b+ cells out of all tumor cells in
the three cell lines, in both groups (total). This is
divided to Ly6G cells (bottom section of each bar,
white), and Ly6G+ (granulocytic) cells (top section of
each bar, black). *p < 0.001. (B) shows representative
FACS tracings of CD11b versus Ly6G expression in
each of the lines. The number in each quadrant is the
percentage of the total tumor cells.
(C and D) Flow cytometry was performed on digested
lungs with orthotopic tumors from mice with the condi-
tionally expressed, K-rasG12D allele, treated for
1 week with control (white) or SM16 (black) chow
(n = 5 per group). (C) summarizes the percentage of
the different CD11b+ cells out of all lung cells ±
SEM—Ly6G+ (granulocytic) cells (left) and Ly6G cells
(right). *p < 0.05. (D) shows representative FACS trac-
ings of CD11b versus Ly6G expression in the two
groups. The numbers shown are the percentage of
total lung cells.RESULTS
Inhibition of TGF-b Signaling Increases Intratumoral
CD11b+ Cells that Express Neutrophil, Ly6G+,
Rather than Macrophage, Ly6G, Markers
To evaluate the role of myeloid (CD11b+) cells, mice bearing
established flank tumors from three syngeneic models were
fed with chow containing SM16 or control chow. Tumors were
harvested and subjected to FACS to detect CD11b+ cells and
different myeloid cell markers.
As shown in Figures 1A and 1B, administration of SM16
increased the percentage of CD11b+ cells in the tumors by
30%–45% (p < 0.02). To differentiate macrophages from neutro-
phils, we used the 1A8 anti-Ly6G antibody, which is found only
on neutrophils (Daley et al., 2008). SM16 treatment led to signif-
icant increases in the percentage of intratumoral Ly6G+ cells and
only minor changes in the Ly6G cells (mostly macrophages). As
seen in Figure 1B, virtually all the Ly6G+ cells were also CD11b+.
To determine whether neutrophils travel to areas of tumor
necrosis, we performed immunohistochemistry of tumors using
the Ly6G antibody. We found an increased number of Ly6G+
cells in tumors from SM16-treated mice and found that the cells
were primarily in the non-necrotic areas of the tumors (see
Figure S1 available with this article online). We also blocked
TGF-b activity using a neutralizing anti-TGF-b monoclonal anti-
body (1D11) in the AB12 cell line and confirmed significantly
increased levels of intratumoral neutrophils (CD11b+/ Ly6G+)
(data not shown).
Evaluation of myeloid cell populations in the spleens of mice
treated with SM16 versus control showed no significant changes
in the percentage of CD11b+ cells (12.1 ± 4.7 in control-treated
versus 13 ± 0.7 in SM16-treated mice), CD11b+/GR1+ myeloid-
derived suppressor cells (10.7 ± 4.3 versus 11.7 ± 0.7), or
CD11b+/Ly6G+ cells (9.2 ± 3.8 versus 9.6 ± 0.6). There was no
change in the percentage of CD11b+/Ly6G+ neutrophils in the184 Cancer Cell 16, 183–194, September 8, 2009 ª2009 Elsevier Incblood in control tumor-bearing mice (41.3% of leukocytes)
versus SM16-treated mice (38.3% of leukocytes). The per-
centage of CD11b+/Ly6G in the blood was negligible in both
groups of mice. These data suggest that the changes in TAN
were not systemic, but rather due to a change in recruitment
and/or persistence within the tumors.
To evaluate the morphology of the TANs, intratumoral
CD11b+/Ly6G+ cells were isolated. As seen in Figure 2, the
Ly6G+ cells isolated from flank tumors from both control un-
treated mice and SM16-treated mice had a clear neutrophil-
like morphology. Interestingly, however, most of the neutrophils
in the SM16-treated tumors were more lobulated and hyperseg-
mented (bottom panel), losing some of the characteristic circular
nuclei appearance typical of blood or bone marrow murine
neutrophils (top panel), that was relatively maintained in control
TAN (middle panel).
We further evaluated the pulmonary influx of CD11b+ cells in
the orthotopic transgenic activated K-ras model of bronchogenic
adenocarcinoma of the lung. Eight to nine weeks after activation
of the K-ras mutation, we treated the mice with SM16 or control
chow followed by flow cytometry of the whole lung. As seen in
Figures 1C and 1D, we found a 43% increase in the percentage
of neutrophils in the lungs of the SM16 mice (8 ± 0.5) compared
with the control mice (5.6 ± 0.9) (p = 0.03). Similar to the results in
the flank models, the percentage of CD11b+/Ly6G cells in
control (2.8 ± 0.7) versus SM16-treated (2.1 ± 0.5) mice did not
increase.
TGF-b-Blockade Increases the mRNA
for Neutrophil Chemoattractants
We next used real-time RT-PCR to measure the level of cyto-
kines, chemokines, and cell adhesion molecules in flank tumors
derived from AB12, LKR, and TC1 cells. As we have shown previ-
ously (Kim et al., 2008; Suzuki et al., 2007), SM16 treatment
resulted in changes in the tumor microenvironment manifested.
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Polarization of TAN by TGF-bby increased levels of iNOS, cytokines, and cell adhesion mole-
cules, along with decreased levels of arginase (Table S1).
We also assessed the message levels of selected chemokines
that have an established role in the recruitment and chemoat-
traction of neutrophils (Kobayashi, 2008). As shown in Table
S1, we found a significant increase of 2- to 5-fold in the mRNA
levels of three potent neutrophil chemoattractants: MIP-2a/
CXCL2, LIX/CXCL5, and MIP1a/CCL3 in all three syngeneic
tumors. We also found a 2- to 3-fold increase in two other neutro-
phil chemoattractants in two of the lines—Rantes/CCL5 (in AB12
and LKR) and KC/CXCL1 (in AB12 and TC1) —as well as a 2-fold
increase in the CXCL1 protein in AB12 tumors (data not shown).
In the TC1 tumor, but not in the AB12 tumor, we found a signifi-
cant 7-fold increase in GM-CSF, another known neutrophil
chemoattractant (Wang et al., 1988). To evaluate a potential
source of these chemokines, we isolated mRNA from TAMs of
Figure 2. The Morphology of TAN in Control and SM16-Treated Mice
Compared to Bone-Marrow Neutrophils
Photomicrograph slides from bone marrow neutrophils (top panel) and from
previously sorted CD11b+/Ly6G+ cells from control (middle panel) or SM16-
treated mice (bottom panel). Scale bars, 10 mm.CAB12 tumors. We found a 2.5- to 3-fold increase in the mRNA
levels of CXCL2 and CXCL5 in isolated macrophages (CD11b+
Ly6G) of tumors from SM16-treated mice, with no change in
CXCL1 levels. These findings suggest that the blockade of
TGF-b by SM16 induces secretion of neutrophil chemoattrac-
tants, at least partially from tumor macrophages, and expression
of adhesion molecules, both of which could augment the recruit-
ment of neutrophils into the tumor.
Intratumoral Neutrophils Are Important Effector Cells in
the Antitumor Effect of Anti-TGF-b Receptor Treatment
We next studied the functional significance of TAN in the AB12
model by depleting the Ly6G+ cells in untreated and SM16-
treated tumor-bearing animals.
We first injected the 1A8 antibody or isotype-matched control
IgG intraperitoneally. A significant reduction of 80%–90% in
systemic and intratumoral neutrophils was noted by FACS in
these experiments (data not shown). Depletion of neutrophils
in non-SM16 treated mice resulted in a small reduction in tumor
growth (Figure 3A). In contrast, depletion of neutrophils in SM16-
treated mice resulted in a significantly reduced effect of SM16
(Figure 3B)—that is, the tumors grew more rapidly when neutro-
phils were depleted in the SM16-treated mice. Interestingly,
when the systemic neutrophils returned in 3 to 4 days after the
last injection, the growth inhibition with SM16 treatment ap-
peared to also return (Figure 3B, last time point).
To determine whether local depletion of neutrophils had
a similar effect, we injected the antibodies at lower dose, directly
into the tumors using a previously described approach (Chen
et al., 2007; Yu et al., 2005) (Figures 3C and 3D). Using flow cy-
tometry, we confirmed a 70%–80% reduction in the percentage
of intratumoral Ly6G+ cells. Local depletion of neutrophils in non-
SM16-treated animals resulted in a small but significant slowing
of tumor growth (p < 0.05) (Figure 3C). Again, in contrast, when
animals were treated with SM16 and also had neutrophils
depleted, the SM16-induced treatment effect was significantly
blunted. Treatment with SM16 reduced tumor burden by 80%–
90%, compared with controls in the nondepleted mice, but
tumor size was reduced by only 40% compared with controls
in the mice that received SM16 plus repeated intratumoral deple-
tion of Ly6G+ cells (Figure 3D). It should be noted that after intra-
tumoral injection, we also found a 30%–50% reduction in blood
neutrophils (data not shown), suggesting that the antibody may
also have a systemic effect. Together, these data indicate that
depletion of neutrophils causes a significant reduction in the
antitumor effect of TGF-b blockade, suggesting that neutrophils
contribute to the antitumor activity of TGFb blockade.
Inhibition of TGF-b Signaling In Vivo Increases CD11b+
Cell Cytotoxicity via an Oxygen Radical-Dependent
Mechanism
To evaluate the cytotoxic potential of the intratumoral myeloid
cells, microbeads were used to purify CD11b+ cells from AB12
tumors, resulting in more than 90% purity (by FACS) in all exper-
iments (data not shown). The isolated CD11b+ cells were cocul-
tured at varying ratios with luciferase-labeled AB12 tumor cells,
and the number of viable tumor cells was determined after 24 hr.
CD11b+ cells from untreated control mice were found to be
noncytotoxic up to a ratio of 20:1 (macrophage to tumor cell),ancer Cell 16, 183–194, September 8, 2009 ª2009 Elsevier Inc. 185
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Polarization of TAN by TGF-bFigure 3. Effect of Neutrophil Depletion on
Tumor Growth and on Tumor Response to
SM16
(A and B) Systemic depletion. Mice (n = 6–8 for
each subgroup) bearing large AB12 tumors, were
treated with either control (A) or SM16 chow (B),
starting at day 13. One group on each diet was
injected with either 100 mg of the anti-Ly6G mono-
clonal antibody 1A8 intraperitoneally (IP) (arrow-
heads) every 3–5 days during the experiment
(triangles, with dashed lines) or a control IgG anti-
body at the same schedule and dose (diamonds
with solid lines). (A) compares mean tumor size ±
SEM with or without Ly6G depletion (Ly6G-dep)
in mice treated with control chow. (B) compares
mean tumor size ± SEM with or without Ly6G
depletion in mice treated with SM16 chow. Groups
were compared using ANOVA. *p < 0.05.
(C and D) Intra-tumoral depletion. The experiment
was repeated again with injection of 30 mg of the
anti-Ly6G monoclonal antibody 1A8 or control
IgG given intratumorally (IT; arrowheads). Groups
were compared using ANOVA. *p < 0.05.whereas CD11b+ cells isolated from the tumors of SM16-treated
mice showed dose-dependent cytotoxicity, with significantly
more killing than control myeloid cells at ratios of 10:1 and
20:1 (Figure 4A). Figure 4B shows data from six independent
experiments with a CD11b+/tumor ratio of 20:1. The average
killing induced by coculture of CD11b+ cells from SM16-treated
mice with AB12 cells was 41.6% versus 16.3% in coculture with
CD11b+ cells from control mice (p = 0.00013). Similar results
were found with evaluation of LKR tumor cells cytotoxicity,
assessed by LDH levels (data not shown).
To evaluate possible mechanisms of killing by the intratumoral
CD11b+ cells, tumor explants were isolated and put in medium
for 24 hr. Tumors from SM16-treated mice secreted 40% higher
levels of NO (p = 0.08; Figure 4C). In contrast, we found no
change in the secretion of TNF-a (Figure 4D). Furthermore, the
level of hydrogen peroxide (H2O2) secretion in PMA-activated
CD11b+ cells from SM16 treated-tumors was 45% higher than
in CD11b+ cells isolated from control mice (p < 0.05) (Figure 4E).
Moreover, there was no reduction in tumor cell killing in the
presence of either anti-mouse TNF-a antibodies or N-methyl-
arginine (NMA), an inhibitor of NO synthase (iNOS). In contrast,
the blockade of superoxide and H2O2 by the addition of super-
oxide dismutase (SOD) and catalase (Cat), respectively, signifi-
cantly reduced the cytotoxicity of the CD11b+ cells to tumor
cells, reducing the killing to 20.8% (p = 0.0039), a level lower
than the killing induced by control CD11b+ cells. These data
show an important role for oxygen radicals in this in vitro assay
of myeloid cell-induced tumor cytotoxicity.
CD11b+ Cell Cytotoxicity Is Primarily Due
to Activated Neutrophils
CD11b+ cells were next sorted using flow cytometry to separate
the TAMs and TANs. We confirmed that the percentage of Ly6G+
cells (by flow cytometry) and neutrophilic-like cells (by morpho-
logic appearance) in the isolated neutrophils was >95%
following isolation. Control TAM, control TAN, SM16 TAM, and186 Cancer Cell 16, 183–194, September 8, 2009 ª2009 Elsevier IncSM16 TAN were cocultured for 24 hr with AB12 cells, and cyto-
toxicity to tumor cells was assessed. At ratios equal or lower than
10 viable neutrophils/macrophages to each tumor cell, there was
no significant killing by either TAMs or TANs (data not shown).
Even at a ratio of 20 macrophages per tumor cell, TAMs from
control mice were mildly supportive to tumor growth. TAMs
from SM16-treated mice and TANs from control mice had small
amounts of killing capacities (up to 10%). The only cells able to
induce significant tumor cytotoxicity were the TANs from the
SM16-treated mice, which at a ratio of 20:1, showed a killing
rate similar to whole CD11b+ cells (about 40% killing) (Figure 4G).
These data show that the TANs make a significant contribution to
the direct tumor cytotoxicity of myeloid cells following TGF-b
blockade.
We further evaluated the expression of surface expressed
‘‘killing’’ molecules on TANs and found low expression of FAS-
ligand and TRAIL by flow cytometry on TANs from both the
control and SM16-treated mice. However, the percentage of
FAS+ neutrophils increased in the tumors from SM16-treated
mice by 25% (14.3% ± 1.3 of neutrophils in control mice versus
18.3% ± 1.4 in SM16-treated mice; p < 0.05), with a similar
increase in the mean fluorescence intensity (MFI) of FAS in the
neutrophils (31.4 ± 2.5 versus 37.2 ± 1.4; p = 0.05).
The TANs Present after TGF-b Blockade Have a More
Immunostimulatory mRNA Profile Than Do TANs
from Untreated Mice
To study other phenotypic changes in the neutrophils following
TGF-b blockade, we performed real-time RT-PCR of selected
receptors, chemokines, and cytokines in TANs. For comparison,
we also examined mRNA levels in neutrophils isolated from the
bone marrow of naive mice and TAMs (CD11b+/Ly6G cells)
from control, tumor-bearing mice. We normalized all values to
the levels found in TANs from control animals (Table 1).
Bone marrow neutrophils had undetectable levels of arginase,
iNOS, CCL3, CCL5, and CCL2, whereas (with the exception of.
Cancer Cell
Polarization of TAN by TGF-biNOS) these genes were highly expressed in control TANs from
AB12 tumors (left panel, Table 1). Unlike many of the other cyto-
kines examined, however, TNF-a and VEGF message levels were
detected in bone marrow neutrophils from naive mice at similar
levels as in control TANs. A similar pattern was seen in LKR
tumors (right panel, Table 1), except that basal VEGF levels in
bone marrow neutrophils were only 10% of those found in TANs.
Of even more interest was the effect of TGF-bblockade on TAN
gene expression. In both types of tumors, control TANs were
found to have high levels of arginase, an important immunosup-
pressor of the adaptive immune system (Rodriguez and Ochoa,
2008). In fact, the levels of arginase message in control TANs
were equal to or even higher than those in control TAMs.
However, arginase levels were 2- to 5-fold lower in TANs from
mice treated with SM16. In contrast, the level of TNF-a mRNA,
an important immunostimulator, was significantly increased
with TGF-b blockade by more than 7-fold in AB12 TAN and 2.4-
fold in TANs from LKR tumors. The levels of CCL2 and CCL5
were significantly lower in SM16-treated TANs (AB12 tumors),
whereas CCL3 was 2- to 2.7-fold higher in AB12 or LKR-bearing
Figure 4. SM16 CD11b+ cell Cytotoxicity Is
Primarily Due to Activated Neutrophils, via
an Oxygen Radical-Dependent Mechanism
(A and B) AB12 tumors (n = 5–7 for each group)
from control and SM16-treated animals were
treated for 7 days and then digested and pooled.
Isolated CD11b+ cells were cocultured with
AB12-luciferase cells at different ratios of effector
cells (CD11b+) to tumor cells. At 24 hr, the
percentage of tumor cells killed was calculated.
(A) summarizes the percentage of tumor killing ±
SEM at each ratio of coculture (n = 4–6). *p <
0.002. In (B), the individual data from six separate
experiments with coculture at a ratio of 20 effector
cells to 1 tumor cell is shown.
(C and D) Pieces of harvested tumors from control
and SM16-treated mice were cultured in medium
for 24 hr, and the secretion of NO (C) and TNFa
(D) per mg of tissue was evaluated. The bars
represent mean ± SEM. &p = 0.08.
(E) Isolated CD11b+ cells were cultured in wells
and activated with PMA, followed by evaluation
of the release of H2O2. The bars represent
mean ± SEM. *p < 0.05.
(F) CD11b+ cells were cocultured with AB12-Luc
cells as above (A and B) and different inhibitors
were added. The bars represent mean ± SEM.
*p < 0.05; **p < 0.01.
(G) CD11b+ cells were sorted using anti-Ly6G anti-
body to neutrophils (Ly6G+) and macrophages
(Ly6G). Each of the cell subtypes were cocul-
tured with tumor cells at a ratio of 20 effector cells
to 1 tumor cell, and cytotoxicity was evaluated as
above. The bars represent mean ± SEM.
SM16-treated mice. ICAM-1 mRNA levels
were markedly increased in SM16-
treated neutrophils (6.7- to 36.4-fold).
The level of ICAM-1 surface expression
was increased by about 2-fold in the
neutrophils of SM16-treated mice, as
shown by flow cytometry (7.4% ± 0.1% of neutrophils in control
mice versus 12.6% ± 0.8% in SM16-treated mice, p < 0.01).
mRNA for VEGF was reduced by 2-fold in the LKR SM16-treated
tumors but had only a nonsignificant trend to reduction in the
AB12 tumor.
We also analyzed neutrophils isolated from lungs of tumor-
bearing mice with advanced tumors from the orthotopic K-ras
model and found very similar differences between the neutro-
phils in the SM16-treated mice and those from the control,
untreated mice (middle panel, Table 1).
Antitumor Activity, as Well as Neutrophil Recruitment
to the Tumors of SM16-Treated Mice, Is Dependent
on the Presence of CD8+ T Cells
Given that systemic CD8+ T cell depletion essentially eliminates
the effect of TGF-b blockade on tumor growth (Suzuki et al.,
2007) and in light of our data showing that the antitumor effect
was also partially neutrophil dependent (Figure 3), we wanted
to explore the intratumoral connections between TANs and
CD8+ T cells.Cancer Cell 16, 183–194, September 8, 2009 ª2009 Elsevier Inc. 187
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Polarization of TAN by TGF-bTable 1. Real-Time RT-PCR Analysis of Neutrophil Subsets with and without Treatment with SM16
Balb/C B6X129/J1





Control SM16 p value Control Control SM16 p value Control SM16 p value Control
Arginase ND 1 0.19 < 0.001 0.3 ND 1 0.04 < 0.001 1 0.55 0.05 1.05
TNFa 0.9 1 7.5 < 0.001 1.3 0.5 1 1.4 0.04 1 2.4 0.008 0.7
ICAM1 9.1 1 36.4 < 0.001 66.7 0.9 1 2.4 < 0.001 1 6.7 0.002 0.8
INOS ND ND ND NA 1 ND ND ND NA 1 1.4 0.14 1.7
CCL3 / MIP1a ND 1 2 0.002 ND ND 1 0.64 < 0.001 1 2.7 0.02 0.9
VEGF 0.5 1 0.8 0.17 0.25 0.1 1 1.1 NS 1 0.5 0.04 0.6
CCL5 / RANTES ND 1 0.38 0.01 0.5 1 0.37 0.025
CCL2 / MCP-1 ND 1 0.18 0.006 0.4 1 0.27 < 0.001
Comparison of mRNA expression from purified neutrophils (CD11b+ Ly6G+) of pooled flank tumors or whole lungs containing Kras-derived tumors from
animals treated with control or SM16 chow, naive bone-marrow-derived neutrophils (BM), and purified control macrophages (Macs., CD11b+ Ly6G).
The fold change of each molecule, using the expression level in untreated control neutrophils as the denominator, was calculated. Data are shown from
two different mice strains: Balb/C and B6X129/J1. p value, between levels in control- and SM16-treated mice. ND, not detected; NA, not applicable;
NS, not significant.We first evaluated the effect of CD8+ T cell depletion on the
phenotype of the tumor-associated myeloid cells. Animals
bearing AB12 tumors were treated with SM16 with or without
CD8+ T cell depletion. Systemic administration of anti-CD8 anti-
body resulted in depletion of more than 90% of CD8+ cells from
the spleen (data not shown). As shown in Figure 5A (and similar
to our previous data), all of the antitumor effect of SM16 was lost
with CD8+ T cell depletion. Given complete loss of efficacy, we188 Cancer Cell 16, 183–194, September 8, 2009 ª2009 Elsevier Indid not try to combine depletion of CD8 and depletion of neutro-
phils in the SM16-treated animals. However, we did study
combined depletion of CD8 cells and neutrophils in control,
untreated mice. As shown in Figure 5B (left columns), and similar
to our findings in Figure 3, intratumoral depletion of neutrophils
led to a slowing of tumor growth. However, even though the
tumors grew faster (as expected after CD8 depletion), we noted
that the mild, but significant, anti-tumor effect of neutrophilFigure 5. CD8+ Cell Depletion Blocks All of
the SM16 Clinical Effect and Reduces Influx
of Neutrophils to the Tumors
(A) Mice (n = 5–6 for each group) bearing large
AB12 tumors were treated in one of four ways:
(1) control chow (diamonds, control); (2) SM16
chow starting at day 13 and throughout the exper-
iment (squares, SM16); (3) control chow, and
injected with 300 mg of an anti-CD8 monoclonal
antibody IP twice per week starting 2 days prior
to tumor injection (triangles, CD8 dep.); and (4)
SM16 chow and depletion of CD8+ cells (crosses,
CD8-dep - SM16). Control and SM16 groups were
treated with an IP control IgG antibody. The bars
represent mean ± SEM. *p < 0.05; **p < 0.01,
control versus SM16; &p < 0.05 control versus
SM16 (both with CD8 depletion).
(B) Mice were injected with either 300 mg of an anti-
CD8 monoclonal antibody IP twice per week start-
ing 2 days prior to tumor injection (right, CD8
depleted) or control IgG (left, no depletion).
When tumors reach a size of 100 mm3, each of
these two groups (n = 10–12 for each group) was
divided to two subgroups, treated for 2 weeks
with either a control IgG antibody (Control, black)
or 100 mg of an anti-Ly6G monoclonal antibody
IT twice per week (a-Ly6G, white), followed by tumor measurements. The bars represent mean size ± SEM of each group. Although CD8 depletion accelerated
tumor growth, the reduction in tumor growth following Ly6G depletion was maintained in this group (right panel). Differences in both groups were significant
(*p < 0.05).
(C and D) Mice (n = 4–5 for each group) bearing large AB12 tumors were treated in one of four ways as above. Seven days after starting treatment with SM16, flow
cytometry of the tumors was performed. (C) summarizes the percentage of CD11b+, Ly6G+, Ly6C+, and CD11b+ Ly6G cells in the four groups out of the total
number of tumor cells ± SEM, *p < 0.05. (D) shows representative FACS tracings of CD11b versus Ly6G expression in each of the four treatment groups. The
number in each panel is the percentage of the total tumor cells.c.
Cancer Cell
Polarization of TAN by TGF-bFigure 6. Neutrophil Depletion Increases CD8+ T Cell Activity in Untreated Mice, but Reduces CD8+ T Cell Activity in SM16-Treated Mice
Mice (n = 5 for each group) bearing large AB12 tumors were treated in one of four ways: control chow (control); SM16 chow (SM16); control chow and injected with
100 mg of the anti-Ly6G monoclonal antibody 1A8 IP twice per week (Ly6G-dep); or SM16 chow and depletion of neutrophils (Ly6G-dep + SM16). The groups not
treated with Ly6G depletion (Control and SM16) were treated with a control IgG antibody at the same schedule and dose. Seven days after starting SM16 or
control chow, multicolor flow cytometry of tumors was performed. Activation of the CD8+ T cells was measured using the activity marker 4-1BB (CD137).
T cell activation was compared with and without neutrophil depletion in the control-chow-treated tumor bearing mice (left columns) and SM16-treated tumor-
bearing mice (right columns) tumors. (A) summarizes the percentage of 4-1BB+ out of total intratumoral CD8+ T cells ± SEM. (B) summarizes the mean fluorescent
intensity (MFI) of 4-1BB in the intratumoral CD8+ T cells ± SEM. *p < 0.01. (C) shows representative FACS tracings of CD8 versus 4-1BB expression in each of the
four treatment groups. The number in the upper right quadrant is the percentage of 4-1BB+ cells out of total CD8+ cells.depletion was maintained (Figure 5B, right columns). These data
suggest that the neutrophils do have some protumor effect that
is independent of the presence of CD8 CTLs.
Consistent with the data shown in Figure 1, the percentage of
CD11b+/Ly6G+ cells in the non-CD8-depleted tumors increased
with SM16 treatment from 3.6% to 6.4% (p < 0.05) (Figure 5C).
CD8 depletion, by itself, reduced the percentage of neutrophils
in the tumor to 1.7% of the cells (p < 0.05). Recruitment of neutro-
phils after treatment with SM16 in the CD8+ T cell-depleted mice
was somewhat blunted, increasing to 2.4% of the cells; however,
this was less than control untreated, nondepleted tumors (Fig-
ure 5C and individual panels in Figure 5D). This small increase
in the percentage of neutrophils was not sufficient to induce an
antitumor growth effect, as noted in Figure 5A.
Depletion of Neutrophils Affects the
Activation of CD8+ CTLs
To understand the effect of TANs on CD8+ T cell activation, we
evaluated the expression of two established surface activation
markers, 4-1BB (CD137) and CD25. Tumor-bearing animals
were left untreated or given SM16 chow with or without neutro-
phil depletion. Tumors were harvested 1 week after SM16 treat-
ment and subjected to FACS. As we have previously shown (Kim
et al., 2008; Suzuki et al., 2007; Wallace et al., 2008), SM16 treat-
ment led to activation of CD8+ T cells compared with controls,
with the percentage of cells positive for 4-1BB increasing from
35.1% to 65.8% of the CD8+ T cells (p < 0.05) and the MFI of
4-1BB increasing from 18.1 to 42.6 (p < 0.01) (Figure 6).
Ly6G+ depletion slightly increased the percentage of intratu-
moral CD8+ cells in control mice (NS) and did not change this
percentage in SM16-treated mice (data not shown). However,
depletion of neutrophils in control mice (having a ‘‘protumor’’Cphenotype) led to significantly increased CD8+ T cell activation:
72.6% of the cells were found to be 4-1BB+ in tumors from
neutrophil-depleted, untreated mice versus 35.1% in control
mice (p < 0.01; Figures 6A and 6C). The MFI of 4-1BB in these
CD8+ T cells increased from 18.1 to 36.9 in control versus
depleted mice (p < 0.01; Figure 6B). This increased activation
of CD8+ cells in control tumor-bearing mice following neutrophil
depletion is consistent with the decreased tumor growth in
neutrophil-depleted mice (Figure 3A and 3C).
We then studied the effect of neutrophil depletion on CD8+
T cell activation in SM16-treated animals. Depletion of these
neutrophils (having an ‘‘antitumor’’ phenotype) led to significant
decreases in CD8+ T cell activation. The percentage of 4-1BB+
activated cells was reduced from 65.8% of the CD8+ T cells to
only 49.7% (p < 0.01; Figure 6A and 6C), and the MFI was
reduced from 42.6 to 18.7 (p < 0.01; Figure 6B). These results
suggest that neutrophil depletion impairs both SM16-induced
activation of CD8+ T cells and SM16-mediated tumor growth
inhibition (see Figure 3). Similar results of CD8 activity were
found when the percentage of CD8+ /CD25+ was evaluated
(data not shown).
DISCUSSION
Polarization of TAN Phenotype: ‘‘N1’’ Versus ‘‘N2’’ TAN
Various types of myeloid cells have been shown to promote
tumor progression by direct immune suppression (Mantovani
et al., 2002), as well as by producing angiogenic factors,
matrix-degrading enzymes, or growth factors (Balkwill and Cous-
sens, 2004; Luo et al., 2006). The best characterized have been
TAMs, which have properties of alternatively activated macro-
phages, also known as M2 macrophages (Mantovani et al., 2002).ancer Cell 16, 183–194, September 8, 2009 ª2009 Elsevier Inc. 189
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Polarization of TAN by TGF-bOur results indicate that, like TAMs, TANs also have differential
states of activation/differentiation, suggesting a classification
scheme for TANs similar to that of TAMs: TANs can thus take
an antitumorigenic (what we are calling an ‘‘N1 phenotype’’)
versus a protumorigenic (‘‘N2’’) phenotype. The antitumor activ-
ities of N1 TANs include expression of more immunoactivating
cytokines and chemokines, lower levels of arginase, and more
capability of killing tumor cells in vitro. Since blockade of TGF-b
favors the accumulation of N1 TANs that have antitumor activity,
our data suggest that TGFb is a major proximal cytokine within
tumors that defines the TAN phenotype and skews differentia-
tion toward the N2 protumorigenic phenotype. This hypothesis
is consistent with previous in vitro data showing that TGF-b
can inhibit neutrophil activity and cytotoxicity (Shen et al.,
2007). Our findings were similar in two different tumor types
(NSCLC and mesothelioma), in three different mice strains, and
in both flank and orthotopic (K-ras) models, suggesting that
the polarization of neutrophils may be a general feature of tumor
microenvironment.
The presence of different TAN phenotypes explains our Ly6G
depletion data and may help to explain some of the apparent
contradictions in the literature. In untreated tumors, neutrophils
have been reported to support tumor growth by producing angio-
genic factors and matrix-degrading enzymes (Pekarek et al.,
1995; Shojaei et al., 2008), support the acquisition of a metastatic
phenotype (Tazawa et al., 2003), and suppress the antitumor
immune response (Schmielau and Finn, 2001). These observa-
tions are consistent with the hypothesis that most TANs appear
to have an N2 phenotype and thus contribute to tumor growth
and immunosuppression. Depleting these protumorigenic N2
neutrophils would thus be expected to inhibit tumor growth.
This explanation is consistent with at least two other earlier
studies (Nozawa et al., 2006; Pekarek et al., 1995) and with our
data showing that depleting neutrophils slowed tumor growth,
even in the absence of CD8+ cells (Figures 3 and 6).
In contrast, when neutrophils assume a more tumor-cytotoxic
N1 phenotype—for example, during TGF-b inhibition (our study)
or after immunologic or cytokine activation—they have the
potential to kill tumor cells and inhibit growth (Colombo et al.,
1992a; Di Carlo et al., 2001; Hicks et al., 2006), as well as coor-
dinate adaptive immune responses through interactions with
dendritic cells (Van Gisbergen et al., 2005). Depletion of these
N1 TANs would thus either augment tumor growth and/or blunt
the antitumor effects of immunologic treatments (Kousis et al.,
2007; Stoppacciaro et al., 1993; Suttmann et al., 2006). This is
exactly what we observed when we depleted neutrophils in the
SM16-treated animals (Figure 3).
Our definition of TAN subsets in tumors has some similarities
to phenotypic and functional distinct neutrophil populations
reported in inflammation and infection models, both in vitro
(Buckley et al., 2006) and in vivo (Itou et al., 2006; Tsuda et al.,
2004). However, the neutrophil subsets in the Tsuda scheme
were defined by morphology, not surface markers. In fact,
some of their proposed neutrophil subsets did not express
CD11b+, nor were there consistent differences in the secretion
of TNF-a. It is likely that distinct differentiation programs occur
in different disease states depending on the cytokine milieu.
One important feature of our study was the use of a highly
neutrophil-specific monoclonal antibody against Ly6G (1A8) to190 Cancer Cell 16, 183–194, September 8, 2009 ª2009 Elsevier Incdifferentiate macrophages (CD11b+/Ly6G) from neutrophils
(CD11b+/Ly6G+), as well as to specifically deplete neutrophils.
This contrasts with most previous studies that used the mono-
clonal antibody RB6-8C5 directed against the granulocyte
receptor 1 (GR-1) surface antigen (Daley et al., 2008). It is now
recognized that the RB6 antibody identifies two epitopes: one
on the neutrophil-specific receptor, Ly6G, and a second epitope
on Ly6C, an antigen expressed by many other cell types (Daley
et al., 2008).
Role of TGF-b in TAN Recruitment
Neutrophils, like all other leukocytes, move into tissues from the
blood under the influence of specific chemokines, cytokines
(e.g., TNF-a and IFN-g), and cell adhesion molecules located
on their own surface (e.g., CD11b) and on the surface of endo-
thelial cells (e.g., selectins, ICAM-1, and PECAM-1) (Kobayashi,
2008). TGF-b appears to inhibit endothelial adhesiveness for
neutrophils and neutrophil transmigration through endothelium
in vitro (Smith et al., 1996) and in different inflammatory disease
states (Allen et al., 2008).
Our data show that TGF-b receptor blockade increases the
number of neutrophils in tumors and suggests that this effect
occurs through all three parts of the recruitment pathway,
including increased expression of mRNA for CXC chemokines,
CC chemokines, and activating cytokines within the tumor (Table
S1), as well as up-regulating ICAM-1 message and protein
expression on endothelial cells (Table S1; see also Kim et al.,
2008). Our preliminary data show that macrophages, as well as
endothelial cells, are the most important in neutrophil recruit-
ment, as previously shown in lung inflammation (Maus et al.,
2003).
It is worth considering the relationship between TANs and
myeloid-derived suppressor cells (MDSCs; Figure 7). Splenic
and blood MDSCs are a heterogeneous population of immune
suppressive cells, excessively produced in cancer, that can be
either monocytic (Ly6C+) or granulocytic (Ly6G+) and function
as systemic immune suppressors and promoters of tumor angio-
genesis (Gabrilovich and Nagaraj, 2009; Movahedi et al., 2008;
Youn et al., 2008). It has been previously shown that MDSCs
can enter tumors and differentiate to mature macrophages
(TAMs) or neutrophils (TANs) (Kusmartsev et al., 2005). Since
we have no definitive markers yet, we do not know whether the
N2 neutrophils within the tumors are actually granulocytic
MDSCs of splenic origin that were attracted to the tumor or
whether they are blood-derived neutrophils that were then con-
verted to an N2 phenotype by the tumor microenvironment,
specifically by the high local concentrations of TGF-b. Given
the fact that we saw no effects of TGF-b blockade on the
percentage of total blood neutrophils, splenic myeloid cells
(CD11b+), or splenic MDSCs, it appears that TGF-b blockade
changes only the local chemoattraction and/or the intratumoral
education of neutrophils, rather than changing the general
phenotype of myeloid cells.
Interaction of TANs with CD8+ T Cells
The role of TGF-b on the function of T cells in vitro and in vivo has
been well established through inhibitor studies (Ge et al., 2006;
Kim et al., 2008; Nam et al., 2008; Suzuki et al., 2007) and
through studies in transgenic mice where a dominant negative.
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Polarization of TAN by TGF-bFigure 7. The Origin and Differentiation of Myeloid-Derived Tumor Associated Cells, as Based on Murdoch et al. (2008) and Gabrilovich and
Nagaraj (2009)
Myeloid-derived tumor-associated cells originate from a common pluripotent stem cell, but separate early to monocytic and granulocytic lineages, eventually
infiltrating tumors. As we show in the current study, TAN can polarize to either antitumor N1 TANs or protumor N2 TANs, with TGF-b being an important effector
in that polarization. The characteristics of the polarized TANs, as presented in the current study, are framed in the bottom right part of the figure.TGF-b receptor has been expressed specifically in T cells (Gor-
elik and Flavell, 2000). Given the importance of CD8+ cells on the
antitumor effect of TGF-b blockade (see also Figure 5A), we also
studied the interplay between TANs and cytotoxic CD8+ cells
and found that TAN depletion affected the phenotype of intratu-
moral CD8+ T cells; however, the results were dependent on the
phenotype of the TANs. Neutrophil depletion of untreated tumor-
bearing animals (i.e., removal of N2 TANs) increased the activa-
tion status of CD8+ T cells. In contrast, neutrophil depletion of
SM16-treated tumor-bearing animals (i.e., removal of N1 TANs)
decreased the activation status of the intratumoral CD8+
T cells, compared with T cells in the animals treated only with
SM16 (Figure 6). These data support the idea that N2 TANs func-
tion in an immunosuppressive fashion, whereas N1 TANs are
immunostimulatory.
The ability of neutrophils to influence CD8+ T cells has been
suggested in infections (Tvinnereim et al., 2004) and in cancer
(Colombo et al., 1992b; Di Carlo et al., 2001; Kousis et al.,
2007); however, interpretation of these studies in the light of
differential neutrophil activation status within tumors is instruc-
tive. Proinflammatory, or N1, neutrophils promote CD8+ recruit-
ment and activation by producing T cell-attracting chemokines
(e.g., CCL3, CXCL9, and CXCL10) and proinflammatory cyto-
kines (e.g., IL-12, TNF-a, GM-CSF, and VEGF) (Scapini et al.,
2000). There is also evidence that they can activate dendritic
cells via cell-cell contact and through secretion of TNF-a (Van
Gisbergen et al., 2005). N2 neutrophils do not produce high
levels of such proinflammatory agents but do produce large
amounts of arginase (Table 1), which would serve to inactivate
T cell effector functions in the same way that has been proposed
for M2 TAMs (Movahedi et al., 2008; Rodriguez et al., 2004).
Although there is an extensive literature on the ability of
neutrophils to recruit CD8+ T cells, as discussed above, there
are surprisingly few studies examining the effect of CD8+
T cells on the recruitment of neutrophils. It has been shown
that CD8+ T cell depletion decreases the tissue influx of neutro-Caphils in infectious diseases (Appelberg, 1992). In the only tumor
study we were able to identify, a marked decrease in TANs
following CD8+ T cell depletion was shown in a model in which
CT26 colon carcinoma cells transduced to express G-CSF
were placed into mice (Stoppacciaro et al., 1993). The mecha-
nisms by which T cells might attract and/or activate neutrophils
are not known for certain, but they include the ability of tumor-
stimulated activated T cells to produce GM-CSF (Aruga et al.,
1997), MIP2, and KC (Sherwood et al., 2004), or cytokines
such as TNFa and IFN-g. These cytokines may act to recruit
neutrophils by stimulating tumor macrophages or endothelial
cells to produce appropriate chemokines and cell adhesion
molecules (Iking-Konert et al., 2008; Maus et al., 2003). Interest-
ingly, without a basal level of tumor microenvironment ‘‘activa-
tion’’ provided by CD8+ T cells, as we see here in our CD8-deple-
tion studies, blockade of TFG-b is apparently not sufficient to
induce neutrophil migration.
Our data suggest at least two different polarized populations
of TANs, protumorigenic and antitumorigenic, similar to what
is seen in macrophages. This paradigm could explain some of
the apparent contradictions in the evaluation of the role of
neutrophils in tumor biology.
EXPERIMENTAL PROCEDURES
Animals
Mice were purchased from Taconic Labs (Germantown, NY), and Jackson
Labs (Bar Harbor, ME). The Animal Use Committee at the University of
Pennsylvania approved all protocols in compliance with the Guide for the
Care and Use of Laboratory Animals.
Cell Lines
The murine malignant mesothelioma cell line, AB12, was derived from an
asbestos-induced tumor in a Balb/C mouse. TC1 cells were derived from
mouse lung epithelial cells from a C57B6 mouse, immortalized with HPV-16
E6 and E7, and transformed with the c-Ha-ras oncogene (Kim et al., 2008).
The murine lung cancer line LKR was derived from an explant of a pulmonaryncer Cell 16, 183–194, September 8, 2009 ª2009 Elsevier Inc. 191
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F1 hybrid of 129Sv.J and C57BL/6 (Wilderman et al., 2005).
Animal Flank Tumor Models
Mice were injected on the right flank with 1 3 106 AB12, LKR, or TC1 tumor
cells in the appropriate syngeneic host. The flank tumors were allowed to reach
an average size of 200–250 mm3 (12–15 days). Following treatments as
outlined below, tumor growth was followed with measurement twice weekly.
All experiments had at least five mice per group and were repeated at least
two times. When needed (i.e., for FACS, RNA, cell subsets isolation, and so
forth), flank tumors were harvested from the mice, minced, and digested
with 2 mg/ml DNase I (Sigma, St. Louis, MO) and 4 mg/ml collagenase type
IV (Sigma) at 37C for 1 hr.
K-ras Mutated Orthotopic Lung Cancer Model
The orthotopic lung cancer model using intratracheal Ad.Cre in transgenic
K-ras mice has been previously described in detail (Wilderman et al., 2005).
Briefly, to activate the conditional oncogene and induce tumors, 100 ml of
saline with 3 3 1010 particles of adenovirus containing Cre recombinase
(Ad.Cre) were administered to LSL KrasG12D mice intranasally. Eight to nine
weeks after instillation of Ad.Cre, mice were treated with SM16 or control
chow for 1 week and sacrificed. Lungs were excised, minced, and subjected
to either flow cytometry or cell purification.
SM16, a TGF-b Receptor Kinase Inhibitor
The chemical structure and biochemical characteristics of SM16, a 430MW
ALK4/ALK5 kinase inhibitor produced by Biogen Idec, has been previously
published (Fu et al., 2008). SM16 formulated into chow at a dose of 0.45 g/kg
of chow results in therapeutic drug levels and has a measurable clinical effect
on tumors (Kim et al., 2008; Suzuki et al., 2007). We further confirmed that oral
administration of SM16 using formulated chow for 5 days significantly
decreases the phosphorylated Smad2 level in AB12 (Figure S2A) and LKR
(Figure S2B) tumors. Tumor-bearing mice were treated with SM16 or control
chow ad libitum. In some experiments, we confirmed our results using the
anti-TGFb monoclonal antibody 1D11 and an isotype-matched IgG1 mono-
clonal antibody, 13C4, provided by Genzyme Corp (Nam et al., 2008). One
hundred mg of the antibody was injected intraperitoneally twice per week.
Flow Cytometric Analysis of Tumors and Spleen
after SM16 Treatment
Splenocytes, blood leukocytes, lungs, and tumor cells were studied by FACS
analysis as previously described (Kim et al., 2008; Suzuki et al., 2007). The
following fluorescently labeled antibodies were purchased from BD Biosci-
ence: CD8-FITC, CD8-PE, CD8-APC, CD11b-FITC, CD11b-PercP, CD11b-
APC, Ly6G-FITC, Ly6G-PE, CD25-FITC, and isotype controls (FITC, PE,
PercP, and APC). CD206-PE was obtained from Serotec (Oxford, UK).
4-1BB (CD137)-PE was obtained from Abcam (Cambridge, UK). All flow
cytometry was done using a Becton Dickinson FACS Calibur flow cytometer
(San Jose, CA). Data analysis was done using FlowJo software (Ashland, OR).
In Vivo Depletion of CD8 T Cells and Ly6g+ Neutrophils
To evaluate the specific role of CD8 T cells and neutrophils in the SM16 model
and the interactions between these cells, we depleted them using monoclonal
antibodies (mAb) to CD8 and/or the neutrophil marker Ly6G. Details on the
mAb and the protocol used can be found in the Supplemental Data.
Isolation of CD11b+ Cells and Separation of Neutrophils
and Macrophages
Tumors were harvested and digested as previously described, and CD11b+
cells were isolated using magnetic beads (Miltenyi Biotec, Germany) per
manufacturer’s instructions to purity of greater than 90% CD11b+ cells. In
some experiments, the positive CD11b+ cells were further sorted using a Beck-
man-Coulter EPICS Elite ESP FACS Sorter (Fullerton, CA) to CD11b+/Ly6G+
(neutrophils) and Cd11b+/Ly6G (mostly macrophages).
For isolation of naive neutrophils, mice were euthanized, and bone marrow
was harvested by flushing the femurs and tibias with HBSS media. Cells were
separated by centrifugation over a 3-layer discontinuous Percoll gradient, as
previously described (Nick et al., 2000).192 Cancer Cell 16, 183–194, September 8, 2009 ª2009 Elsevier InEvaluation of the Morphology of Tumor Neutrophils
For the evaluation of the morphology of TANs in control and SM16-treated
mice, slides from previously sorted CD11b+/Ly6G+ cells were prepared by
centrifugation at 1,500 rpm for 10 min in a Shandon Cytospin 3 (Shandon
Lipshaw, Inc., Pittsburgh, PA). The neutrophils on the slides were stained using
a Hemacolor kit (EM Science, Gibbstown, NJ). Cells were evaluated under light
microscopy (3100).
RNA Isolation and Real-Time, Reverse Transcription-PCR
Pooled RNA from tumors of control and SM16-treated mice was isolated, and
the quantification of tumor mRNA levels was performed as previously
described (Suzuki et al., 2005). Details on this method and primer sequences
can be found in the Supplemental Data.
Immunohistochemical Staining of Tumors
Animals bearing flank tumors were euthanized and the tumors were immedi-
ately placed in Tissue-Tek OCT compound (Sakura Finetek USA, Inc.,
Torrance, CA) to be stored at 80C, followed by Sectioning and staining.
Monoclonal antibodies against leukocytes (anti-CD45), macrophages (anti-
CD11b), and Ly6G+ cells (anti-Ly6G) were obtained from BD Biosciences.
Evaluation of Tumor Cytotoxicity by Immune Cell Subsets
We evaluated tumor cytotoxicity using the AB12 mesothelioma-cell line trans-
fected with a luciferase reporter (AB12-Luc), cocultured with immunocytes.
The mechanism of killing was done using specific inhibitors. Details on this
method and the inhibitors can be found in the Supplemental Data.
Evaluation of Secretion of Cell Products
We evaluated the secretion of NO and TNF-a in whole tumor explants. Details
on this method can be found in Supplemental Data.
Statistical Analyses
For the RT-PCR, FACS studies, and flank tumor studies comparing differences
between two groups, we used unpaired Student t tests. For FACS and flank
tumor studies comparing more than two groups, we used one sided ANOVA
with appropriate post hoc testing. Differences were considered significant
when p < 0.05. Data are presented as mean ± SEM.
SUPPLEMENTAL DATA
Supplemental Data include two tables, two figures, and Supplemental Exper-
imental Procedures and can be found with this article online at http://www.cell.
com/cancer-cell/supplemental/S1535-6108(09)00215-3.
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